Overcoming Hypoxia-Induced Functional Suppression of NK Cells

Articles

May 28, 2020

Kristen Solocinski 1, Michelle R Padget 1, Kellsye P Fabian 1, Benjamin Wolfson 1, Fabiola Cecchi 2, Todd Hembrough 2, Stephen C Benz 3, Shahrooz Rabizadeh 2 4, Patrick Soon-Shiong 2 4, Jeffrey Schlom 1, James W Hodge 5
Affiliations expand
PMID: 32345623 PMCID: PMC7213912 DOI: 10.1136/jitc-2019-000246
Read Full Article

Contact us at

+1-844-MY NK CELLS (+1-844-696-5235)

Visit Newsroom

Solutions for Patients

ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Next-generation adenovirus-vectored anti-cancer vaccines make appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research.

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.

About Us